U.S. Hospitality Stock News

NasdaqGM:OCS
NasdaqGM:OCSPharmaceuticals

Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation

Oculis Holding (NasdaqGM:OCS) is back on investor radars after its neuroprotective candidate Privosegtor received FDA breakthrough therapy designation for optic neuritis, supported by Phase 2 ACUITY data and advancement into registrational PIONEER trials. See our latest analysis for Oculis Holding. The FDA breakthrough therapy news has arrived alongside a 10.3% 7 day share price return and a 10.2% year to date share price return, while the 1 year total shareholder return of 17.8% and very...
NasdaqGM:LFMD
NasdaqGM:LFMDHealthcare Services

LifeMD (LFMD) Is Up 17.3% After Expanding Telehealth Access To Wegovy Oral Pill – What’s Changed?

In early January 2026, LifeMD announced it is now offering Novo Nordisk’s newly FDA-approved Wegovy (semaglutide) pill through its nationwide telehealth platform, expanding virtual access to an oral GLP-1 option for chronic weight management and cardiovascular health at cash-pay prices starting from US$149 per month for eligible patients. This move deepens LifeMD’s collaboration with Novo Nordisk and positions the company more firmly in the fast-growing obesity care segment by pairing...
NasdaqGS:PHAT
NasdaqGS:PHATPharmaceuticals

Why Phathom Pharmaceuticals (PHAT) Is Down 6.0% After $130 Million Equity Raise And 2025 Guidance Update

Phathom Pharmaceuticals recently completed a roughly US$130.0 million follow-on offering of common stock and pre-funded warrants, alongside new shelf registrations covering additional common stock and other securities, and issued earnings guidance indicating expected net revenues of about US$57.0 million–US$58.0 million for fourth quarter 2025 and US$174.5 million–US$175.5 million for full-year 2025, with operating profitability targeted in the second half of 2026 excluding stock-based...
NYSE:TUYA
NYSE:TUYASoftware

Is Tuya (TUYA) Fairly Priced After Recent IoT Platform Focus And Share Price Gains

If you are wondering whether Tuya's current share price lines up with its underlying worth, you are not alone. This article is built to help you size up what you are really paying for. Tuya's stock last closed at US$2.22, with returns of 5.2% over the past week, a 3.5% decline over the last 30 days, and gains of 1.4% year to date and 37.9% over the last year, while the three year return sits at a 7.9% decline. Recent headlines around Tuya have focused on its role as a software provider in...
NYSE:WHD
NYSE:WHDEnergy Services

Is It Time To Reassess Cactus (WHD) After Recent Share Price Rebound?

If you are wondering whether Cactus shares still offer value at around US$51.37, you are not alone. This article focuses on what that price could mean for long term investors. The stock has recently moved, with returns of 12.5% over the last 7 days, 12.4% over the last 30 days, 9.2% year to date and an overall 12.5% decline over the last year, while the 5 year return stands at 85.5% and the 3 year return at a 3.3% decline. These swings have put Cactus back on the radar for investors who...